Francisco Cervantes
Impact in
- Genetics top 0.01%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Papers in
- Genetics 243
- Myeloproliferative Neoplasms: Diagnosis and Treatment 166
- Chronic Lymphocytic Leukemia Research 77
- Hematology 212
- Chronic Myeloid Leukemia Treatments 139
- Acute Myeloid Leukemia Research 77
- Multiple Myeloma Research and Treatments 20
- Co-authors
- Alessandro M. Vannucchi (54 shared papers)Giovanni Barosi (33 shared papers)Francesco Passamonti (45 shared papers)Michele Baccarani (17 shared papers)Ayalew Tefferi (27 shared papers)Arturo Pereira (35 shared papers)Tiziano Barbui (28 shared papers)Claire Harrison (41 shared papers)
- Journals
- Blood (73 papers)British Journal of Haematology (23 papers)Annals of Hematology (22 papers)Journal of Clinical Oncology (20 papers)Leukemia (18 papers)
- Partner nations
- SpainItalyUnited States
In The Last Decade
Francisco Cervantes
312 papers receiving 19.7k citations
Francisco Cervantes's Hit Papers
Peers
Comparison fields: 5 of 128
- Genetics 14.8k
- Hematology 13.0k
- Rheumatology 5.8k
- Molecular Biology 6.4k
- Pathology and Forensic Medicine 919
Countries citing papers authored by Francisco Cervantes
This map shows the geographic impact of Francisco Cervantes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisco Cervantes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisco Cervantes more than expected).
Fields of papers citing papers by Francisco Cervantes
This network shows the impact of papers produced by Francisco Cervantes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisco Cervantes. The network helps show where Francisco Cervantes may publish in the future.
Co-authors
The 25 scholars most cited alongside Francisco Cervantes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 322 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis Hit paper breakdown → | 2012 | 1244 |
| 2 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet Hit paper breakdown → | 2009 | 892 |
| 3 | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Hit paper breakdown → | 2008 | 840 |
| 4 | Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Hit paper breakdown → | 2017 | 814 |
| 5 | Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Hit paper breakdown → | 2010 | 812 |
| 6 | Prognostic discrimination in "good-risk" chronic granulocytic leukemia Hit paper breakdown → | 1984 | 724 |
| 7 | DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status Hit paper breakdown → | 2010 | 674 |
| 8 | Prognostic discrimination in "good-risk" chronic granulocytic leukemia Hit paper breakdown → | 1984 | 654 |
| 9 | A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) Hit paper breakdown → | 2009 | 639 |
| 10 | Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Hit paper breakdown → | 2007 | 604 |
| 11 | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Hit paper breakdown → | 2007 | 542 |
| 12 | 2006 | 447 | |
| 13 | Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis Hit paper breakdown → | 2016 | 357 |
| 14 | Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis Hit paper breakdown → | 2015 | 348 |
| 15 | 2013 | 299 | |
| 16 | 2008 | 273 | |
| 17 | 2013 | 246 | |
| 18 | 2017 | 245 | |
| 19 | 2008 | 227 | |
| 20 | 2017 | 220 |
About Francisco Cervantes
Francisco Cervantes is a scholar working on Genetics, Hematology, Rheumatology, Molecular Biology and Pathology and Forensic Medicine, having authored 322 papers that have together received 20.1k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (166 papers), Chronic Myeloid Leukemia Treatments (139 papers), Acute Myeloid Leukemia Research (77 papers), Chronic Lymphocytic Leukemia Research (77 papers), Eosinophilic Disorders and Syndromes (76 papers), Kruppel-like factors research (40 papers), Lymphoma Diagnosis and Treatment (24 papers) and Multiple Myeloma Research and Treatments (20 papers). The work is most often cited by research in Genetics (14.8k citations), Hematology (13.0k citations), Rheumatology (5.8k citations), Molecular Biology (6.4k citations) and Pathology and Forensic Medicine (919 citations). Francisco Cervantes has collaborated with scholars based in Spain, Italy and United States. Frequent co-authors include Alessandro M. Vannucchi, Giovanni Barosi, Francesco Passamonti, Michele Baccarani, Ayalew Tefferi, Arturo Pereira, Tiziano Barbui, Claire Harrison, Alberto Álvarez‐Larrán and Heinz Gisslinger. Their work appears in journals such as Blood, British Journal of Haematology, Annals of Hematology, Journal of Clinical Oncology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.